Randomized clinical trial (RCT) of IFN-intolerant/ineligible (II) GT1 patients (TN or TE) including LDV/SOF failures with NS5A RAVs using SMV+SOF+/-RBV for 12/24 weeks
Introduction: In a real-world database, retreatment of LDV/SOF failures with SMV+SOF +/- RBV for 12 or 24 weeks achieved 86% SVR [6/7], however, there was no randomization ... unknown whether RBV was beneficial. A…

